Indivior Receives Health Canada Approval for Sublocade (SC) (Buprenorphine Extended-Release) in Patients with Moderate to Severe Opioid Use Disorder(OUD)

 Indivior Receives Health Canada Approval for Sublocade (SC) (Buprenorphine Extended-Release) in Patients with Moderate to Severe Opioid Use Disorder(OUD)

Indivior Receives Health Canada Approval for Sublocade (SC) (Buprenorphine Extended-Release) in Patients with Moderate to Severe Opioid Use Disorder(OUD)

Shots:

  • The approval of Sublocade(qmt) in combination with medication-assisted treatment (MAT) is indicated to treat OUD in adults, using Atrigel delivery system
  • The clinical trials demonstrated, that Injection site reactions were reported in 16% of the patients. None of the injection site reactions were serious and one led to study treatment discontinuation
  • Health Canada has approved Sublocade, post USFDA approval in 30th Nov’2017, and will be available for patients in H2’19

Click here to read full press release/ article | Ref: Indivior | Image: Qualsys

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post